(TheNewswire)
Toronto, Ontario, March 25, 2019 / TheNewswire / Ventripoint
Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that the University of Ottawa Heart
Institute has ordered the VMS+ complete heart analysis system for the clinical assessment of cardiac patients.
The new system will be used to do research into valvular heart disease, infective endocarditis and aortic
diseases with a specific focus in the application of ultrasound in the study of cardiac structure and function.
Function of the right ventricular (RV) is increasingly recognized as an important predictor of outcome in
various forms of heart disease. Although cardiac magnetic resonance (CMR) is accepted as the reference standard in the assessment
of RV volume and function, its use is hindered by limited accessibility. Echocardiography (echo) is widely used in the
assessment and follow-up of patients with suspected RV dysfunction, but it suffers from suboptimal endocardial visualization,
inability to visualize the entire RV and only a qualitative rather than a quantitative assessment.
The initial research focus will be on patients with tricuspid regurgitation, testing the hypothesis that RV
volume determined by the Ventripoint system can be used as a more reliable and quantitative method to assess and follow patients
with tricuspid regurgitation.
The VMS+ system uses Artificial Intelligence (AI) to provide a streamlined approach for volumetric measurements
and ejection fractions for all 4 chambers of the heart from standard 2D echo images. It is also the only approved way to generate
substantially equivalent results to the gold-standard MRI.
About University of Ottawa Heart Institute
The University of Ottawa Heart Institute (https://www.ottawaheart.ca) has flourished into one of Canada’s
most distinguished heart health centres for the unparalleled care it provides to its patients, a world-renowned research Institute
that brings science from bench to bedside, and the country’s main influencer when it comes to preventing heart disease. Its
promise remains the very pillar on which it was built: Always putting patients
first.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has
developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac
care.
For further information please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other
factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most
recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news
release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news
release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required
by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Copyright (c) 2019 TheNewswire - All rights reserved.